ClinicalTrials.gg
CompletedNCT00138008Updated Sep 22, 2016

Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy

A Phase 3 interventional study of endocrine therapy and radiotherapy in Prostate Cancer, sponsored by Haruhiko Fukuda. Completed at 34 sites in Japan. Open to male participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2016-09-22.

Sponsored by Haruhiko Fukuda · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Prostatic Neoplasms with a site in Japan — 36 open to participants now, 69 under way, 30 of them phase 3. Prostatic Neoplasms · Japan.

Enrollment
71st of 116
200 · median 351
Started
2004
with 1 other
Phase 3
52 of 133
12 open now
Registered
2nd of 133
by date

Among the 133 studies in Prostatic Neoplasms with a site in Japan, this one is the 71st largest by enrollment of the 116 interventional ones that give a count, is one of 2 that started in 2004, is one of 52 in phase 3, and was the 2nd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

36 of the 133 studies in Prostatic Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 20 Years to 79 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Prostatic Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in comparison with endocrine therapy alone for PSA failure after radical prostatectomy.

Read the detailed description

A randomized controlled trial is conducted in Japan to evaluate radiotherapy followed by endocrine therapy for PSA failure after radical prostatectomy. Patients who have PSA failure after radical prostatectomy under a diagnosis of localized prostate cancer (T1-2 N0M0) are randomized into treatment group of either radiotherapy followed by endocrine therapy or endocrine therapy alone. Urologic Oncology Study Group (UOSG) in the JCOG composed of 36 specialized institutions will recruit 200 patients. The primary endpoint is time to treatment failure (TTF) of bicalutamide and secondary endpoints are TTF of protocol treatment, progression free survival, overall survival, adverse events and quality of life (QOL). The Clinical Trial Review Committee of the Japan Clinical Oncology Group (JCOG) approved the protocol on April 13, 2004, and the study was activated on May 17, 2004.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • prostate cancer
  • radical prostatectomy
  • PSA failure
  • RCT
  • radiation
  • endocrinotherapy
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of localized prostate cancer (clinical stage T1-2N0M0) which is treated by radical prostatectomy
  • Pathological stage: pT0/2/3 and pN0/x
  • Serum level of PSA once reached \< 0.1 ng/ml after radical prostatectomy and then increased 0.4 ng/ml
  • Serum level of PSA 1.0 ng/ml at entry
  • No clinical recurrence based on abdominal and pelvic computed tomography, and a bone scan
  • No history of chemotherapy or radiation therapy or endocrine therapy for any cancer
  • Ages 20 to 79 years
  • (ECOG) performance status of 0 or 1
  • No blood transfusion within 28 days of entry
  • Sufficient organ function within 28 days of entry
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Synchronous or metachronous (within 5 years) other than carcinoma in situ
  • Mental disease or mental symptoms which would affect participant's decision to participate
  • Continuous medication with (exclude external use of steroids for skin)
  • Ischemic heart disease or arrhythmia which needs medical treatment
  • Poorly controlled hypertension
  • Poorly controlled diabetes mellitus
  • History of cerebral infarction or myocardial infarction within 6 months
  • Liver cirrhosis
  • Interstitial pneumonia which requires ventilation assistance, oxygen inhalation, steroids, or diuretic medicine
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    1

    Drug: endocrine therapy

    Drug: endocrine therapy

  • Experimental
    2

    Procedure/Surgery: radiotherapy

    Procedure: radiotherapy

Interventions

  • Drugendocrine therapy

    Drug: endocrine therapy

  • Procedureradiotherapy

    Procedure/Surgery: radiotherapy

06

What researchers measure

Primary outcomes

  1. time to treatment failure (TTF) of bicalutamide

    Time frame: time to treatment failure (TTF) of bicalutamide

Secondary outcomes

  1. TTF of protocol treatment

    Time frame: TTF of protocol treatment

  2. clinical progression free survival

    Time frame: time to clinical progression

  3. overall survival

    Time frame: overall

  4. adverse events

    Time frame: overall

  5. patient-reported quality of life

    Time frame: 1 year

07

Study locations

34 sites
  • Nagoya University School of Medicine
    Nagoya,Showa-ku,Tsurumai-cho,65, Aichi 466-8550, Japan
  • Akita University School of Medicine
    Akita,Hondo,1-1-1, Akita 010-8543, Japan
  • Chiba University, Graduate School of Medicine
    Chiba,Chuo-ku,Inohana,1-8-1, Chiba 260-8670, Japan
  • Chiba Cancer Center Hospital
    Chiba,Chuo-ku,Nitona-cho,666-2, Chiba 260-8717, Japan
  • National Hospital Organization Shikoku Cancer Center
    Matsuyama,Horinouchi,13, Ehime 790-0007, Japan
  • Graduate School of Medical Science, Kyushu University
    Fukuoka, Higashi-ku,Maidashi,3-1-1, Fukuoka 812-8582, Japan
  • Kurume University School of Medicine
    Kurume,Asahi-machi,67, Fukuoka 830-0011, Japan
  • Gunma University
    Maebashi,Showa,3-39-15, Gunma 371-8511, Japan
  • Hokkaido University Hospital
    North-14 West-5 Kita-ku,Sapporo, Hokkaido 060-8648, Japan
  • Sapporo Medical University
    S-1,W-16,Chuo-ku,Sapporo, Hokkaido 060-8543, Japan
  • Kobe University Graduate School of Medicine
    Kobe,Chuo-ku,Kusunoki-cho,7-5-2, Hyogo 650-0017, Japan
  • Institute of Clinical Medicine,Tsukuba University Hospital
    Tsukuba,Tennodai,1-1-1, Ibaraki 305-8575, Japan
  • Faculty of Medicine, Kagawa University
    Kita,Miki-cho,Ikenobe,1750-1, Kagawa 761-0793, Japan
  • Kagoshima University,Faculty of Medicine
    Kagoshima,Sakuragaoka,8-35-1, Kagoshima 890-8520, Japan
  • Kitasato University School of Medicine
    Sagamihara,Kitasato,1-15-1, Kanagawa 228-8555, Japan
  • Kyoto University Hospital
    Kyoto,Sakyo-ku,Syogoinkawara,54, Kyoto 606-8507, Japan
  • Mie University School of Medicine
    Tsu,Edobashi,2-174, Mie 514-8507, Japan
  • Miyagi Cancer Center
    Natori,Medeshima-Shiode,Nodayama,47-1, Miyagi 981-1293, Japan
  • Tohoku University Hospital
    Sendai,Aoba-ku,Seiryo-machi,1-1, Miyagi 980-8574, Japan
  • Sinshu University
    Matsumoto,Asahi,3-1-1, Nagano 390-8621, Japan
  • Nara Medical University
    Kashihara,Shijo-cho,840, Nara 634-8522, Japan
  • Niigata University Medical and Dental Hospital
    Niigata,Asahimachi-dori,1-754, Niigata 951-8520, Japan
  • Niigata Cancer Center Hospital
    Niigata,Kawagishi-cho,2-15-3, Niigata 951-8566, Japan
  • Kurashiki Central Hospital
    Kurashiki,Miwa,1-1-1, Okayama 710-8602, Japan
  • Okayama University Hospital
    Okayama,Shikata-cho,2-5-1, Okayama 700-8558, Japan
  • Osaka Medical Center for Cancer and Cardiovascular Diseases
    Osaka,Higashinari-ku,Nakamichi,1-3-3, Osaka 537-8511, Japan
  • Shimane University Faculty of Medicine
    Izumo,Enya-cho,89-1, Shimane 693-8501, Japan
  • Hamamatsu University School of Medicine
    Hamamatsu,Handayama,1-20-1, Shizuoka 431-3192, Japan
  • Sizuoka Cancer Center
    Sunto-gun,Nagaizumi-cho,Shimonagakubo,1007, Shizuoka 411-8777, Japan
  • Tochigi Cancer Center
    Utsunomiya,Yohnan,4-9-13, Tochigi 320-0834, Japan
  • National Cancer Center Hospital
    Chuo-ku,Tsukiji,5-1-1, Tokyo 104-0045, Japan
  • Jikei University Hospital
    Minato-ku,Nishishinbashi,3-25-8, Tokyo 105-8461, Japan
  • Keio University Hospital
    Shinjuku-ku,Shinanomachi,35, Tokyo 160-8582, Japan
  • University of Yamanashi Faculty of Medicine
    Nakakoma,Tamaho,Shimokato,1110, Yamanashi 409-3898, Japan
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2005
First posted
Aug 30, 2005
Start
May 2004
Primary completionActual
May 2016
CompletionActual
May 2016
Last update
Sep 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00138008
Lead sponsor
Haruhiko Fukuda
Collaborators
Ministry of Health, Labour and Welfare, Japan
Responsible party
Haruhiko Fukuda (JCOG Data Center, Japan Clinical Oncology Group) — Sponsor-investigator
First posted
Aug 30, 2005
Start date
May 2004
Primary completion
May 2016
Completion
May 2016
Last update
Sep 22, 2016

Study contacts

Seiji Naito, MD, Ph.D.
study chair · Graduate School of Medical Science, Kyushu University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion